Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Tremfya biosimilars?

See the DrugPatentWatch profile for Tremfya

Short answer

There are no separate biosimilars of Tremfya—Tremfya itself is a biosimilar. The drug is the branded formulation of adalimumab-atto (the first FDA‑approved adalimumab biosimilar). However, there are other adalimumab biosimilars that compete with Tremfya, such as:

Brand Manufacturer Generic name FDA status Main indications
Amjevita Amgen adalimumab‑atto Approved (interchangeable) RA, AS, PsA, plaque psoriasis, Crohn’s, UC, etc.
Erelzi Pfizer adalimumab‑pf Approved (interchangeable) Same as above
Imraldi Mylan adalimumab‑cbqv Approved (interchangeable) Same as above
Hyrimoz Mylan adalimumab‑hyk Approved (interchangeable) Same as above
Cimzia Novartis adalimumab Reference product (originator) Same as above

Tremfya = Amjevita
Tremfya is the brand name for Amgen’s adalimumab‑atto, so when you see Tremfya you are already looking at a biosimilar. The other names above are other biosimilars of the same active ingredient.


What does that mean for you?

Topic Key points
What is a biosimilar? A biologic that is highly similar to a reference product, with no clinically meaningful differences in safety, purity, and potency.
Switching between biosimilars The FDA has approved all these adalimumab biosimilars as interchangeable, meaning a pharmacist may substitute one for another without prescriber approval.
Insurance & cost Many insurers list only a single “adalimumab” entry that can be filled by any of the interchangeable biosimilars. The price usually varies by manufacturer and pharmacy benefit manager (PBM) contracts.
Clinical considerations The same dosing, route, and safety profile apply to all adalimumab products. Any differences are minimal and are due to manufacturing processes.

Why there’s no “Tremfya biosimilar”

  1. Tremfya is already a biosimilar.
    The original biologic is adalimumab (brand name Humira®). Tremfya (Amjevita) is the first FDA‑approved biosimilar to Humira.
  2. Regulatory definition.
    A biosimilar must have a reference product. Since Tremfya’s reference is Humira, it cannot be “biosimilarized” again—rather it can be “substituted” with other adalimumab biosimilars.

How to decide which adalimumab product to use

Consideration What to look at
Formulary list Check your insurance’s preferred adalimumab.
Manufacturer contract Some PBMs prefer certain manufacturers for cost‑sharing reasons.
Patient preference Injection device, dosing frequency (usually every 2 weeks).
Special circumstances In certain jurisdictions, switching between biologics may require prior authorization or monitoring.

Quick FAQ

Question Answer
Is Tremfya “better” than Humira? No, it’s designed to be therapeutically equivalent.
Can I switch from Tremfya to Amjevita? Yes, the FDA has cleared both as interchangeable.
Will my insurance pay the same? Often yes, if both are listed under the same “adalimumab” benefit.
Do side‑effect profiles differ? No clinically significant differences have been observed.
What about pediatric use? All adalimumab biosimilars are approved for the same indications, including juvenile idiopathic arthritis, at the same doses.

Bottom line

  • Tremfya is itself a biosimilar (Amjevita).
  • There are no additional biosimilars of Tremfya, but there are multiple interchangeable adalimumab biosimilars.
  • Choosing between them usually comes down to cost, insurance coverage, and convenience.

If you’re a prescriber or a patient trying to navigate this, checking the most recent formulary and consulting your pharmacist can help you pick the most cost‑effective option without compromising safety or efficacy.



Other Questions About Tremfya :

What is the Tremfya One-Press injector? Tremfya approval date? Canadian tremfya price? Can tremfya cause weight gain? How effective is tremfya for psoriatic arthritis? Tremfya medication? What is the loading dose schedule for tremfya?